Literature DB >> 24292576

Wogonin, a natural and biologically-active flavonoid, influences a murine WEHI-3 leukemia model in vivo through enhancing populations of T- and B-cells.

Chin-Chung Lin1, Jen-Jyh Lin, Ping-Ping Wu, Chi-Cheng Lu, Jo-Hua Chiang, Chao-Lin Kuo, Bin-Chuan Ji, Ming-Huei Lee, An-Cheng Huang, Jing-Gung Chung.   

Abstract

Wogonin, a natural and biologically-active flavonoid found in plants, has been reported to exhibit anticancer effects on several cancer cell types. However, there is no available information regarding the responses to wogonin in leukemia mouse models. At concentrations of 10-200 μM, wogonin reduced the percentage of viable WEHI-3 cells in a concentration-dependent manner. In an in vivo study, WEHI-3 cells were intraperitoneally injected into normal BALB/c mice for establishing leukemic BALB/c mice to determine the anti-leukemia activity of wogonin. Wogonin increased the survival rate and the body weight of leukemic mice when compared to vehicle (olive oil)-treated groups. Furthermore, the results also revealed that wogonin increased the percentage of cluster of differentiation-3 CD3 (T-cell marker) and CD19 (B-cell marker) but reduced that of Mac-3 (macrophages) and CD11b (monocytes) cell surface markers in treated mice as compared with the untreated leukemia group. Based on these observations, wogonin might exhibit anti-leukemia effects on murine WEHI-3 cell line-induced leukemia in vivo.

Entities:  

Keywords:  BALB/c mice; Wogonin; flavonoid; murine WEHI-3 leukemia model

Mesh:

Substances:

Year:  2013        PMID: 24292576

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

Review 1.  Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors.

Authors:  Xue Wu; Haijun Zhang; Jumah Masoud Mohammad Salmani; Rong Fu; Baoan Chen
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

2.  Genkwanin nanosuspensions: a novel and potential antitumor drug in breast carcinoma therapy.

Authors:  Yijing Li; Jingyi Hong; Haowen Li; Xiaoyu Qi; Yifei Guo; Meihua Han; Xiangtao Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 3.  The Therapeutic Potential of Wogonin Observed in Preclinical Studies.

Authors:  Javad Sharifi-Rad; Jesús Herrera-Bravo; Luis A Salazar; Shabnum Shaheen; Seyed Abdulmajid Ayatollahi; Farzad Kobarfard; Muhammad Imran; Ali Imran; Luísa Custódio; María Dolores López; Mauricio Schoebitz; Miquel Martorell; Manoj Kumar; Hafiz Ansar Rasul Suleria; William C Cho
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-15       Impact factor: 2.629

4.  Apoptotic Mechanism of Human Leukemia K562/A02 Cells Induced by Magnetic Ferroferric Oxide Nanoparticles Loaded with Wogonin.

Authors:  Miao-Xin Peng; Xiao-Yue Wang; Fan Wang; Lei Wang; Pei-Pei Xu; Bing Chen
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.